INT29142

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1987
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 10
Disease Relevance 1.48
Pain Relevance 7.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lyase activity (Pck1) nucleolus (Pck1) nucleus (Pck1)
lipid metabolic process (Pck1) cytoplasm (Pck1)
Anatomy Link Frequency
thalamus 2
Pck1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 28 100.00 Very High Very High Very High
opioid receptor 14 99.84 Very High Very High Very High
MU agonist 11 99.58 Very High Very High Very High
tolerance 5 99.36 Very High Very High Very High
Potency 5 99.26 Very High Very High Very High
Antinociceptive 5 99.16 Very High Very High Very High
Thalamus 5 98.92 Very High Very High Very High
Enkephalin 6 98.56 Very High Very High Very High
Clonidine 4 97.60 Very High Very High Very High
mu opioid receptor 23 97.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Bordatella Infection 4 98.04 Very High Very High Very High
Increased Venous Pressure Under Development 7 93.40 High High
Targeted Disruption 3 87.08 High High
Ganglion Cysts 1 77.88 Quite High
Glioma 4 75.28 Quite High
Cognitive Disorder 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The EC50 for DAMGO was 30 nM, similar to its potency to inhibit cAMP accumulation and to increase [gamma-35S]GTP binding.
Positive_regulation (increase) of GTP Binding (binding) of associated with potency
1) Confidence 0.67 Published 1999 Journal Neuroreport Section Abstract Doc Link 10439458 Disease Relevance 0 Pain Relevance 0.95
The addition of purified GTP-binding proteins caused an increase in the binding to the membranes pretreated with 50 microM NEM, but did not increase [3H]-clonidine binding in membranes treated with 500 microM NEM.
Positive_regulation (increase) of GTP Binding (binding) of associated with clonidine
2) Confidence 0.49 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 2824697 Disease Relevance 0 Pain Relevance 0.44
In sense-treated control cells, DAMGO-stimulated [35S]GTP-gamma-S binding by increasing the B(max) of the high-affinity site.
Positive_regulation (increasing) of GTP Binding (binding) of
3) Confidence 0.49 Published 2004 Journal Synapse Section Abstract Doc Link 15065220 Disease Relevance 0.22 Pain Relevance 0.77
Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
Positive_regulation (receptor-stimulated) of GTP Binding (binding) of in thalamus associated with mu agonist, enkephalin and thalamus
4) Confidence 0.49 Published 1998 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 9580589 Disease Relevance 0 Pain Relevance 0.87
DAMGO stimulated [35S]GTP-gamma-S binding with an anatomical specificity consistent with the localization of mu opioid receptors.
Positive_regulation (stimulated) of GTP Binding (binding) of associated with mu opioid receptor
5) Confidence 0.49 Published 1997 Journal Synapse Section Abstract Doc Link 9329153 Disease Relevance 0 Pain Relevance 0.55
Comparison of the potency of these compounds with their potencies in an in vitro functional model, agonist-induced [35S]GTP gamma S binding, suggests that blockade of dural extravasation was consistent with an action at rat 5-HT1D receptors, but activity at another, unknown, "extravasation receptor" could also be involved.
Positive_regulation (agonist-induced) of GTP Binding (binding) of associated with agonist and potency
6) Confidence 0.49 Published 1997 Journal Neuropharmacology Section Abstract Doc Link 9225277 Disease Relevance 0.61 Pain Relevance 0.61
In membrane assays, with 20 microM GDP, ORL1 peptide stimulated [35S]GTP gamma S binding by approximately two-fold with an ED50 value of 20 nM.
Positive_regulation (stimulated) of GTP Binding (binding) of
7) Confidence 0.49 Published 1996 Journal Neuroreport Section Abstract Doc Link 8733732 Disease Relevance 0 Pain Relevance 0.29
Seven days of chronic sufentanil treatment developed antinociceptive tolerance associated with a reduction in mu-agonist-induced [35S]GTP gamma S binding, mu-agonist-induced adenylyl cyclase inhibition, and co-precipitation of G alpha o, G alpha i2 G alpha z and G alpha q11 subunits with mu-opioid receptors.
Positive_regulation (mu-agonist-induced) of GTP Binding (binding) of associated with mu opioid receptor, agonist, tolerance and antinociceptive
8) Confidence 0.49 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18384820 Disease Relevance 0.17 Pain Relevance 1.07
Sufentanil increased [35S]GTP gamma S binding by 326% with an EC50 value of 2.39 nM.
Positive_regulation (increased) of GTP Binding (binding) of
9) Confidence 0.45 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8819494 Disease Relevance 0.24 Pain Relevance 1.00
Agonist stimulation of [35S]GTP gamma S binding was stereoselective, naltrexone-reversible, and pertussis toxin-sensitive.
Positive_regulation (stimulation) of GTP Binding (binding) of associated with bordatella infection and agonist
10) Confidence 0.45 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8819494 Disease Relevance 0.25 Pain Relevance 1.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox